News Releases

August 2018

August 9, 2018 8/9/2018 Ambys Medicines and Takeda Announce Partnership to Pioneer First-In-Class Therapies for the Treatment of Serious Liver Diseases

August 3, 2018 8/3/2018 Takeda and Whiz Partners Announce Creation Joint Investment Fund Fund Aims to Promote Drug Discovery Ecosystem in Japan

August 1, 2018 8/1/2018 Takeda to Produce Innovative Drug for Multiple Myeloma Patients in Yaroslavl, Russia

July 2018

July 31, 2018 7/31/2018 Takeda Reports First Quarter FY2018 Results

July 31, 2018 7/31/2018 Takeda Completes its Acquisition of TiGenix

July 25, 2018 7/25/2018 Takeda Announces Phase 3 Trial of ALUNBRIG® (brigatinib) Met Primary Endpoint Demonstrating Superiority in Progression-Free Survival Versus Crizotinib in Patients with ALK+ Advanced NSCLC Who are ALK Inhibitor Naïve

July 19, 2018 7/19/2018 Investigational Subcutaneous Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Ulcerative Colitis

July 18, 2018 7/18/2018 Takeda and Ovid Therapeutics Expand Clinical Program for TAK-935/OV935 with Three New Studies in Rare Developmental and Epileptic Encephalopathies (DEE)

July 18, 2018 7/18/2018 Takeda Submits an Application for a New Indication of Entyvio® (vedolizumab) for the Treatment of Adult Patients with Moderately to Severely Active Crohn’s Disease in Japan